Tingting Xu

5PUBLICATIONS
41CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersOncology and carcinogenesis not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Apr 07, 2026
Anti-PD-1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double-blind phase 3 study.

Shuang Huang, Feng Liu, Song Qu

|Nov 13, 2023
Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial.

Xiaomin Ou, Ruiping Zhai, Wenjun Wei

|Jan 28, 2023
Response to induction chemotherapy predicts survival outcomes in oropharyngeal cancer.

Qixian Zhang, Tingting Xu, Chunying Shen

|Jan 12, 2023
CD161 Characterizes an Inflamed Subset of Cytotoxic T Lymphocytes Associated with Prolonged Survival in Human Papillomavirus-Driven Oropharyngeal Cancer.

Ye Wei, Tingting Xu, Chong Li

|Jul 28, 2020
Human papillomavirus (HPV) in Chinese oropharyngeal squamous cell carcinoma (OPSCC): A strong predilection for the tonsil.

Tingting Xu, Chunying Shen, Ye Wei

Pageof 1

Frequent Collaborators

4 joint publications

Xueguan Lu

3 joint publications

Xiayun He

3 joint publications

Chaosu Hu

2 joint publications

Qinghai Ji